Gilead promotes COO John Milligan to CEO; chief executive John Martin named executive chairman

29 January 2016

Gilead Sciences Inc (Nasdaq: GILD) on Friday said chief operating officer John Milligan will be promoted to chief executive, replacing the current chairman and CEO John Martin who will take on the role of executive chairman, both effective March 10, 2016.

John Cogan, Gilead's lead independent director, said: "John Martin has led Gilead as CEO for the past 20 years, and under his stewardship, the company has developed and delivered therapeutic advancements to millions of people around the world. His legacy is clear - and the vision he has set will continue with his contributions as executive chairman."

John Martin joined Gilead in 1990 and was appointed chief executive in 1996 and chairman in 2008. John Milligan also joined Gilead in 1990 and was appointed chief operating officer in 2007.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK